Biologics For Severe Asthma: A Focused Discussion

Some biologic medicines target particular processes involved in severe asthma rather than acting as general rescue medicines. One specific example is Nucala, or mepolizumab, described in its May 2025 US label as an interleukin-5 antagonist monoclonal antibody. That label identifies selected severe eosinophilic asthma, not every person whose symptoms are difficult.

The important question is why a specialist thinks a particular biologic fits your asthma and what result it is intended to improve. The category name alone does not select the treatment or establish that existing medicines are unnecessary.

Table of Contents

Match the proposed medicine to the assessed asthma

The Nucala asthma indication is add-on maintenance treatment for adults and children aged six and older with severe asthma and an eosinophilic phenotype. Age, severity and phenotype are part of that indication. A symptom checklist cannot establish the whole match.

Before an additional medicine is discussed, bring the current inhalers, routine and symptom pattern. UK guidance recommends considering possible reasons for uncontrolled asthma and observing technique. An unresolved device, access or exposure problem should not simply disappear because a biologic is being considered.

Ask which findings support the proposed treatment and what remains uncertain. Do not interpret a laboratory result by itself as an instruction to request a particular product.

Understand the outcome, not a promise of cure

The label reports fewer exacerbations than placebo in its severe-asthma trial program. It defines those events using worsening requiring systemic corticosteroids and/or emergency or hospital care. Patients continued background asthma therapy during the trials.

That supports a discussion about reducing attacks in an appropriately assessed population. It is not a guarantee of no future attacks, proof that every biologic works identically or a personal prediction from a group average.

The label explicitly excludes acute bronchospasm or status asthmaticus relief. Keep the maintenance treatment discussion separate from the instructions for an attack. A scheduled injection is not an emergency replacement for the reliever and help-seeking plan prescribed to you.

Agree how safety and benefit will be reviewed

Nucala’s warnings include hypersensitivity reactions and caution against abruptly discontinuing inhaled or systemic corticosteroids when starting it. Any proposed reduction belongs in the prescriber’s plan. This page gives no taper, injection dose or administration sequence.

Ask what improvement the team will assess, when the review will happen and which problems require contact. Discuss the practical arrangement for obtaining and receiving treatment as well as the intended clinical benefit.

Keep your asthma action plan current with the treating team. The useful decision is a supported, monitored add-on treatment for an assessed need, not a move from inhalers to an imagined risk-free cure.

Sources and scope

This is a dated Nucala label example, not a complete comparison of current biologics. UK assessment guidance has its own population and prescribing context. Not yet medically reviewed.